🌿 Natural  ❘  Effective  ❘  Safe  |  info@mycobind.co.uk
Licensing & Commercialisation
Opportunity Overview: Mycobind is seeking commercial partners, licensees, and co-development collaborators to bring plant-derived protection technology to market. We welcome enquiries from industry, investors, and research institutions.

Licensing Opportunities

The intellectual property underlying Mycobind's plant-derived binding technology is available for licensing under terms suitable for a range of commercial applications. We offer:

  • [License type 1 — e.g. Exclusive territory licence for specific markets or regions]
  • [License type 2 — e.g. Non-exclusive production licence for industrial application]
  • [License type 3 — e.g. Co-development agreement with shared IP ownership]
  • [License type 4 — e.g. Research collaboration with access to our compound library]

Who We Are Looking For

Ideal partners include:

  • [Target partner type 1 — e.g. Animal feed manufacturers seeking natural mycotoxin binders]
  • [Target partner type 2 — e.g. Food safety companies operating in Sub-Saharan Africa or Asia]
  • [Target partner type 3 — e.g. Pharmaceutical or nutraceutical companies in natural antimicrobials]
  • [Target partner type 4 — e.g. Agricultural technology investors or venture funds]
  • [Target partner type 5 — e.g. Academic institutions for co-funded clinical or field trials]

Development Stage

Mycobind is currently at [development stage — e.g. late-stage preclinical / early commercial scale-up]. Laboratory screening across 22+ plant species has identified strong binding candidates with MIC values below the 1 mg/mL cut-off across multiple pathogen and toxin targets. [Add any regulatory, IP, or pilot trial status here.]

IP & Proprietary Position

[Describe the IP position — e.g. patent pending, trade secret, know-how, or data package. State the jurisdiction and filing date if applicable. This section helps partners assess exclusivity and freedom to operate.]

Financial Terms

Licensing terms are negotiated on a case-by-case basis depending on the scope, territory, and application. Indicative structures include:

  • [e.g. Upfront licence fee + royalty on net sales]
  • [e.g. Milestone-based payments tied to regulatory or commercial events]
  • [e.g. Equity co-investment in exchange for development support]

Next Steps

Interested parties are invited to submit an initial enquiry via the contact page or by emailing info@mycobind.co.uk. Please include a brief introduction to your organisation and the nature of your interest. We will respond with a non-disclosure agreement and further product information within [X] business days.

Submit an Enquiry View Research Evidence